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Abstract
The CRISPR/Cas9 system has emerged as an important tool in biomedical research for a wide 
range of applications, with significant potential for genome engineering and gene therapy. In order 
to achieve conditional control of the CRISPR/Cas9 system, a genetically encoded light-activated 
Cas9 was engineered through the site-specific installation of a caged lysine amino acid. Several 
potential lysine residues were identified as viable caging sites that can be modified to optically 
control Cas9 function, as demonstrated through optical activation and deactivation of both 
exogenous and endogenous gene function.
Many bacteria and archaea utilize an adaptive immune defense based on a system of 
clustered regularly interspaced short palindromic repeats (CRISPR) that target invasive 
nucleic acids through the interaction of CRISPR-associated (Cas) proteins and CRISPR 
arrays, which are transcribed and processed into short CRISPR RNAs (crRNAs).1 The 
crRNA guides the Cas proteins to sequence-specific duplex cleavage. Type II CRISPR 
systems employ an additional RNA, the trans-activating crRNA (tracrRNA), which 
hybridizes with the crRNA.2 These two RNAs can be combined to allow Cas9 targeting with 
a single guide RNA (gRNA).3 The Cas9 enzyme has been optimized for site-specific DNA 
cleavage and nicking followed by non-homologous end-joining (NHEJ) or homology-
directed repair (HR), enabling gene editing, gene deletion, and gene mutation4 in human 
cells5 and animal models.6 The ease of customized gRNA design allows for sequence-
specific and highly efficient gene targeting without the need for protein engineering.7 In 
addition, a catalytically inactive Cas9 has been engineered into a transcriptional activator 
and repressor, expanding the utility of Cas9 as a gene regulatory tool.8
Regulation of protein function with light provides control over biological processes with 
unprecedented resolution.9 To date, no optical control of Cas9 activity has been reported. 
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Optically regulating Cas9 function enables precise spatial and temporal control of gene 
editing. Light-activated proteins can be generated in live mammalian cells with an expanded 
genetic code through the site-specific incorporation of caged amino acids in response to a 
recoded amber stop codon, TAG.10 In order to develop a system for optochemical control of 
CRISPR/Cas9 gene editing (Figure 1A), genetic code expansion was used by adding an 
engineered pyrrolysyl tRNA (PylT)/tRNA synthetase (PCKRS) pair to the translational 
machinery of human cells to enable the site-specific incorporation of photocaged lysine 
(PCK, Figure 1C) into proteins.11 Multiple lysines of interest were identified as potential 
caging sites for the inhibition of CRISPR/Cas9 function (Supporting Figure 1). K76, K163, 
K510, and K742 are highly conserved across species and, based on recent crystal 
structures,12 are in close proximity to the gRNA nucleic acid binding sites and thus may be 
essential for Cas9-gRNA interaction. K866 undergoes a significant conformational change 
upon binding of the gRNA, orienting the lysine to become surface exposed, which may be 
necessary to properly position the target DNA strand for cleavage (Figure 1B). However, the 
exact role of this residue has not been determined.
We developed a dual reporter assay (based on pIRG13), which switches from expressing 
DsRed to expressing EGFP in the presence of functional Cas9 and matching gRNAs, and is 
not responsive to UV exposure in the absence of Cas9 (Supporting Figure 2). Two gRNAs 
(Supporting Table 1) were designed to target sequences upstream and downstream of the 
DsRed-terminator cassette. Upon co-expression of Cas9, these gRNAs direct the excision of 
DsRed, and the plasmid is repaired to allow EGFP expression. This assay was used in an 
initial alanine scan of K76, K163, K540, K742, and K866. All Cas9 alanine mutants 
expressed well in HEK293T cells (Supporting Figure 3A), and four of the Cas9 alanine 
mutants were still active (Supporting Figure 4). However, K866 was identified as being 
essential for activity, suggesting it as a potential target for the introduction of PCK. Amber 
stop codon mutations were then introduced at all five lysines of interest, since the K→PCK 
mutation may induce an additional level of perturbation compared to a K→A mutation, and 
Western blots confirmed PCK-dependent expression of the caged Cas9 mutants (Figure 1D 
and Supporting Figure 3B). The function of the caged Cas9 mutants in the presence and 
absence of UV exposure (365 nm, 2 min) was tested using the dual reporter assay (Figure 2). 
The incorporation of PCK at K76, K163, and K866 showed full inhibition of Cas9 activity in 
the absence of UV exposure, while the K742PCK mutant was still functional, similar to 
wild-type. Additionally, the K510PCK mutant showed a low level of undesired background 
activity in the absence of UV exposure. After light-activation, the K163PCK, K510PCK, and 
K866PCK mutants showed successful light-activation of Cas9 as observed through the 
expression of EGFP, while the K76PCK mutant was surprisingly not activated. In contrast to 
wild-type Cas9, all cells expressing light-activated Cas9 mutants still showed DsRed 
fluorescence, since the caged Cas9 activation occurred 24 h after transfection, while the 
wild-type Cas9 was immediately active once expressed. Thus, in the case of light-activated 
Cas9, DsRed protein that has already been expressed persists, with a half-life greater than 4 
days.14
We successfully identified two lysine sites that are amenable to optically control of Cas9 
function, presenting two different pathways for the light-activation of CRISPR/Cas9 gene 
editing: (1) K163, which might interact with the gRNA, and (2) K866, which may play a 
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role in positioning the non-target DNA strand (Supporting Figure 1). The Cas9 K866PCK 
mutant showed minimal background activity before irradiation and high activity after light 
exposure for 2 min, reaching wild-type Cas9 levels (Figure 3A). A UV irradiation time 
course was performed with the K866-caged Cas9 (Supporting Figure 5), demonstrating that 
exposure of >2 min did not further enhance activation. In order to show spatial control of 
CRISPR/Cas9 gene editing in mammalian cells, the activation of K866-caged Cas9 was 
performed through patterned UV irradiation of a layer of HEK293T cells (Figure 3B). The 
mechanism of deactivation by the K163PCK and K866PCK mutations was further analyzed 
through plasmid cleavage assays with purified Cas9 (Supporting Figure 6), showing no DNA 
cleavage or nicking activity in the absence of UV irradiation. The absence of any catalytic 
activity of the caged enzyme suggests that interaction with the gRNA and/or target DNA 
may be inhibited through introduction of PCK, thereby deactivating Cas9 function. Taken 
together, these experiments successfully demonstrate spatial and temporal control of gene 
function using a site-specifically caged Cas9 that is genetically encoded in mammalian cells, 
allowing for conditional light-activation of CRISPR/Cas9 gene editing.
We then demonstrated silencing of an endogenous gene through light-activated gene editing 
using the optically activated Cas9. The transmembrane transferrin receptor CD71 (also 
known as TfR1), associated with leukemia and lymphoma,15 was selected as a target. 
gRNAs for the 5′UTR8 and several exons within the coding region of CD71 were designed 
in order to inhibit protein function via disruption of upstream regulatory elements or 
disruption of the amino acid sequence. First, we confirmed that CD71 knockdown by wild-
type CRISPR/Cas9 could be quantified via both qRT-PCR and phenotype analysis via 
fluorescent antibody staining of HeLa cells. Indeed, we observed repression of CD71 mRNA 
with the 5′UTR targeting gRNA (∼70%) while the exon-targeting gRNAs showed no effect 
on mRNA levels. In addition, reduced levels of CD71 protein (∼75%) were observed for all 
gRNAs, relative to non-treated cells (Supporting Figure 7). Next, CD71 suppression was 
performed with the K866-caged Cas9 in the absence and presence of light-activation. 
Quantification of CD71 mRNA revealed a reduction by approximately 60% only in the case 
of the gRNA targeting the CD71 5′UTR (Figure 4A). This is not surprising, as the 
introduction of mutations into the coding region of the CD71 gene should not affect 
transcription. Light-activation of Cas9 function reduced the presence of CD71 protein on the 
cell surface by approximately 50% (Figure 4B), demonstrating the ability to optically 
control the silencing of endogenous genes with our caged CRISPR/Cas9 system. The 
reduced repression observed for the light-activated K866-caged Cas9 compared to wild-type 
Cas9 (10–25%) may require further optimization for endogenous gene editing applications, 
although the frequency of indels has not been determined, limiting quantitative assessment 
on the genomic level. Thus, our optically activated CRISPR/Cas9 system can be applied to 
the control of endogenous genes on the genomic level.
In summary, we have successfully developed a genetically encoded light-activated CRISPR/
Cas9 system for conditional control of gene editing and gene expression. Through both 
alanine and unnatural amino acid scanning, we identified lysine residues that are important 
for Cas9 function. Of these sites, K866 was shown to be essential for activity and was 
utilized in the generation of a light-activated CRISPR/Cas9 system through incorporation of 
a photocaged lysine at that position. We showed that the genetically encoded caged Cas9 
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could be applied to gene editing—for activation and deactivation—of both fluorescent 
reporters and endogenous genes in human cells. Importantly, the caged enzyme was 
completely inactive before UV illumination, and its activity could be restored up to wild-
type levels through a brief 120 s exposure to 365 nm light. In contrast to recently reported 
light-induced recruitment of a transcriptional activator to a DNA-bound enzymatically 
inactive dCas9,16 our approach allows for regulation of Cas9 function. Moreover, upon light-
induced decaging, wild-type Cas9 is generated. Many cell types and model organisms have 
been modified by Cas9-mediated gene editing,17 demonstrating the broad applicability of 
the CRISPR/Cas9 system. Unnatural amino acid mutagenesis based on the pyrrolysine 
system is expanding into model organisms, such as C. elegans and D. melanogaster,18 
providing future opportunities for optical control of CRISPR/Cas9 function beyond cell 
culture. Light-activation of CRISPR/Cas9 may allow for the study of gene function with 
high precision, and may reduce toxicity from off-target mutations19 by restricting the 
function of Cas9 to certain locations or time points.
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(A) Light-activation of caged Cas9 enables optochemical control of gene editing. The caged 
Cas9 protein contains a site-specifically incorporated photocaged lysine, rendering it 
inactive until the caging group is removed through light exposure. This generates wild-type 
Cas9, which induces sequence-specific DNA cleavage followed by subsequent non-
homologous end-joining (NHEJ) or homology-directed repair (HR). (B) K866 (red) 
conformation before (left) and after (right) gRNA binding to Cas9. Renderings are based on 
PDB 4CMP and 4OO8. (C) Photocaged lysine (PCK), with the photocleavable caging group 
shown in red. (D) Western blot of PCK-dependent Cas9 K866TAG expression.
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Cas9 PCK mutant activity scanning. HEK293T cells were transfected with the caged Cas9 
expression system as well as the dual reporter construct and grown in the presence of PCK 
(2 mM) for 24 h. The cells were kept in the dark or UV irradiated for 120 s and imaged 
(10×) after 48 h. Scale bar indicates 200 μm.
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(A) Analysis of EGFP expression by imaging cytometry. Error bars represent standard 
deviations from three replicates. (B) Spatial control of CRISPR/Cas9 gene editing through 
irradiation of a subset of cells defined by a mask. Imaged at 20× magnification with tile 
stitching (2×3). Scale bar indicates 200 μm.
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Light-activated CRISPR/Cas9 silencing of CD71 in HeLa cells. (A) Quantitative real-time 
PCR analysis of CD71 mRNA, normalized to the GAPDH control gene. (B) Fluorescence 
detection of cell-surface CD71 protein. Data are shown relative to non-irradiated cells for 
each condition, and error bars represent standard deviations from three replicates.
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